Revenues totaled RON478 million, up 25%, and expenses reached RON389 million, 11% higher than in the same period of 2022.
The company posted 32% higher local sales during this period, at RON288.67 million, and 23% higher sales abroad, at RON175.6 million.
Antibiotice carried out RON58 million investments to develop its product portfolio, green energy production, retool labs and logistics.
Moreover, the company attracted RON85 million non-reimbursable funds via state aid and sealed a loan agreement with the EIB worth RON123 million.
The company’s shares have added 117% since the beginning of 2023 amid RON32 million deals.
(English version by Catalina Apostoiu)